This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Pat Phillips

JAMA. 1999;282:929-931.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Vancouver, BC—New pharmaceutical strategies in the treatment of Parkinson disease (PD) are emerging as basic and clinical research burgeons throughout the neurological community worldwide.

Discoveries made by Viennese investigator Oleh Hornykiewicz, MD, in the 1960s—that depletion of dopamine in the brains of patients with PD could be overcome by giving them levodopa—turned Parkinson disease from one of the least understood and least studied of the neurologic diseases to one of the best understood and best studied in terms of chemical changes in the brain, Donald Calne, MD, director of the Neurodegenerative Disorders Centre at the University of British Columbia, Vancouver, said at a recent meeting.

Calne spoke at the 13th International Congress on Parkinson Disease, a biannual meeting of the World Federation of Neurology held under the auspices of the Pacific Parkinsons Research Institute, which he chaired and at which much new research was presented.

NEW DOPAMINE . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?